<DOC>
	<DOCNO>NCT02440958</DOCNO>
	<brief_summary>Pancreatic ductal adenocarcinoma fourth cause death Western world . Surgery remain treatment offering advantage term overall survival ( 5-year survival range , 15-25 % ) , unfortunately 10-20 % patient present resectable disease time diagnosis . Since approval gemcitabine standard treatment advance pancreatic patient , drug combination drug significantly improve prognosis . Recently , compare gemcitabine , FOLFIRINOX associate survival advantage ( 11.1 vs 6.8 month ) , increased toxicity . In retrospective study , modify FOLFIRINOX regimen ( 60/120 mg/m2 oxaliplatin irinotecan ) improve safety profile digestive malignancy . The purpose phase II multicenter study investigate efficacy safety patient pancreatic cancer progress gemcitabine-based first line chemotherapy .</brief_summary>
	<brief_title>Modified FOLFIRINOX Gemcitabine Refractory Pancreatic Cancer : A Phase II Multicenter Trial</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Pathologically confirm pancreatic ductal adenocarcinoma ( metastatic locally advanced stage ) Refractory progress Gemcitabine base 1st line chemotherapy Older 19 year old young 75 year old Life expectancy &gt; 3 month ECOG Performance status ≤2 Only patient measurable lesion image study Adequete BM function ( WBC ≥ 3,500/µl , absolute neutrophil cell count ≥ 1,500 /µl , platelet count ≥ 100,000/µl ) Adequete liver function ( total bilirubin &lt; 1.5 X upper limit normal ( ULN ) , AST ALT &lt; 3 X UNL , alkaline phosphatase &lt; 3 X ULN &lt; 5 x ULN case liver involvement ) Adequete renal function ( serum creatinine &lt; 1.5 mg/dl ) Adequete cardiopulmonary function Pathologically confirm another type pancreatic cancer ( except ductal adenocarcinoma ) Metastatic adenocarcinoma originate organ Evidence CNS metastasis Active infection Uncontrolled serious medical psychiatric illness induce toxicity ro complication treatment , inability swallow , lack physical integrity gastrointestinal tract , malabsorption syndrome , active ulceration upper gastrointestinal tract . Coexisting malignancy within 5 year , except squamous cell carcinoma basal cell carcinoma skin Participation investigational drug study within 1 month No sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>